Jagsonpal Pharmaceuticals Limited — Investor Meet, 29-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharma posted strong Q1 FY27 results. Revenue jumped 9% YoY to ₹82.2 Cr, with Operating EBITDA up 21% YoY to ₹19.1 Cr and margins at 23.2%. Profit After Tax (PAT) grew 22% YoY to ₹13.2 Cr. Management highlighted outperforming the industry, with an 18.9% growth versus 11.6% for IPM. The company completed the Aequitas Healthcare acquisition, marking its entry into hospital supplies, targeting ₹10+ Cr EBITDA from it by Year 2. A ₹40 Cr share buyback was completed, yet cash reserves remained robust at ₹170 Cr. Management is confident about sustained profitable growth and future acquisitions.